MR spectroscopy characteristics of tumefactive demyelinating lesions and glioma patients
| Patient No. | Lesion | Enhancing Region | Central Region | Perilesional T2 Region | Contralateral Normal Brain | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cho/Cr | NAA/Cr | Lac | Cho/Cr | NAA/Cr | Lac | Cho/Cr | NAA/Cr | Lac | Cho/Cr | NAA/Cr | Lac | ||
| 1 | TDL | 4.6 | 1.0 | ++ | 3.5 | 1.0 | ++ | 1.7 | 1.2 | + | 0.5 | 1.6 | − |
| 2 | TDL | 1.8 | 1.9 | + | 3.0 | 3.2 | ++ | 1.6 | 2.9 | + | 0.9 | 1.6 | − |
| 3 | TDL | 1.7 | 0.7 | − | 4.9 | 2.3 | + | 1.9 | 1.2 | − | 0.7 | 1.6 | − |
| 4 | TDL | 2.4 | 1.3 | − | 3.3 | 2.7 | − | 1.5 | 0.3 | − | 0.8 | 2.0 | − |
| 5 | TDL | 2.8 | 1.9 | − | 1.6 | 2.5 | − | 1.4 | 2.6 | − | 1.4 | 3.0 | − |
| 6 | TDL | 1.7 | 1.7 | + | 2.3 | 1.4 | − | 1.1 | 1.7 | − | 0.9 | 1.9 | − |
| 7 | AA | 3.3 | 1.2 | − | 1.5 | 1.2 | − | 1.8 | 2.0 | − | 0.5 | 1.7 | − |
| 8 | AA | 3.3 | 0.7 | − | 9.0 | 1.1 | − | 1.0 | 0.9 | − | 0.7 | 1.2 | − |
| 9 | AO | 0.9 | 0.7 | − | 2.1 | 1.1 | − | 1.3 | 0.9 | + | 0.9 | 1.1 | − |
| 10 | AA | 4.3 | 0.9 | − | 3.8 | 0.8 | − | 2.0 | 1.4 | − | 0.7 | 1.7 | − |
| 11 | AMG | 2.5 | 0.6 | − | 2.5 | 0.6 | − | 2.0 | 1.3 | − | 1.6 | 3.6 | − |
| 12 | AA | 1.3 | 0.6 | − | 1.6 | 0.5 | − | 1.2 | 0.9 | − | 0.9 | 1.4 | − |
| 13 | AMG | 10.3 | 0.8 | + | 11.3 | 1.6 | − | 1.2 | 2.1 | + | 0.8 | 2.0 | − |
| 14 | AA | 12.7 | 0.6 | − | 4.7 | 0.8 | + | 1.5 | 1.3 | − | 1.1 | 1.5 | − |
| 15 | GBM | 1.8 | 0.7 | − | 2.2 | 0.9 | − | 1.5 | 1.2 | − | 1.0 | 1.5 | − |
| 16 | GBM | 10.0 | 1.0 | − | 4.4 | 0.8 | − | 2.3 | 1.0 | − | 1.2 | 2.1 | − |
Note.—TDL indicates tumefactive demyelinating lesion; AA, anaplastic astrocytoma; AO, anaplastic oligodendroglioma; AMG, anaplastic mixed glioma; GBM, glioblastoma multiforme.